Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against mpox with 84% ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

One dose of the Jynneos vaccine was 58% effective against mpox infection overall and 84% in people without HIV, but only 35% ...

In his first term, President Donald Trump launched a bold and successful initiative against HIV. This time around, the ...

Increasing HPV vaccination rates could help decrease the number of cancer cases “attributable to HIV,” according to data from a study presented at the Conference on Retroviruses and Opportunistic ...

Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research published in The Lancet medical journal. The drug lenacapavir passed a critical ...

Survey data suggests that over a third of organizations that relied on US funding for HIV services had already closed by ...

It’s possible that HIV could be prevented by an annual shot — at least, that’s what new data from Gilead suggests. The drug company has been developing a new HIV drug called lenacapavir ...

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...